Summary & Overview
CPT 90689: Inactivated Adjuvanted Quadrivalent Influenza Vaccine, 0.25 mL
CPT code 90689 denotes an inactivated, preservative-free quadrivalent influenza vaccine that includes an adjuvant to enhance immune response and is delivered as a 0.25 mL intramuscular dose. Nationally, influenza vaccination remains a core preventive service with broad public health importance, and codes like CPT code 90689 capture specific vaccine formulations used across ambulatory care settings.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and billing practices for influenza vaccines vary by payer, plan, and provider setting, affecting claims processing and reimbursement workflows.
Readers will learn: the clinical and service context of CPT code 90689; typical places where the vaccine is administered; which major payers are relevant for coverage considerations; and where to find additional coding details. Data not available in the input is noted where applicable. This summary provides a concise reference for health system leaders, billing teams, and clinical staff who manage vaccine administration and claims for this specific influenza product.
Billing Code Overview
CPT code 90689 represents an inactivated, preservative-free, adjuvanted influenza (flu) vaccine formulated to protect against four influenza virus strains. The vaccine is supplied in a 0.25 mL dose and is intended for intramuscular administration.
Service type: Vaccine administration (intramuscular)
Typical site of service: Outpatient clinic, primary care office, pharmacy clinic, public health clinic, or other ambulatory settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric patient aged 6 months to 35 months presents to a primary care clinic during influenza season for routine immunization. The clinician confirms medical history, checks for acute febrile illness or egg allergy concerns, documents prior influenza vaccinations and dosing history, and obtains verbal consent from the parent or guardian. The patient is positioned for an intramuscular injection into the anterolateral thigh (for infants) or deltoid muscle (for older toddlers). The staff prepares a 0.25 mL syringe of inactivated, adjuvanted, preservative-free quadrivalent influenza vaccine and administers it intramuscularly. Post-vaccination observation for 15 minutes is performed to monitor for immediate adverse reactions. Documentation in the medical record includes vaccine lot number, expiration date, dose (0.25 mL), route (intramuscular), site (anterior thigh or deltoid), vaccine product mapped to CPT 90689, informed consent, and any adverse events. Billing is submitted with CPT 90689 for the vaccine product; if relevant, modifier 00 is appended per payer rules to indicate the primary service, with documented use of modifiers 22 (unusual procedural services) or 52 (reduced services) only when appropriate and supported by clinical documentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|